Talk:Access to medicines
This article is rated B-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||||||
|
Untitled
[edit]Hi,
I added several sections--along with pictures and references. The sections I included are on factors that block medication access, related legislation, and global challenges and examples. I kept the rest of your content untouched. ChiaO (talk) —Preceding undated comment added 04:30, 7 March 2018 (UTC)
Wiki Education Foundation-supported course assignment
[edit]This article is or was the subject of a Wiki Education Foundation-supported course assignment. Further details are available on the course page. Student editor(s): ChiaO.
Above undated message substituted from Template:Dashboard.wikiedu.org assignment by PrimeBOT (talk) 16:49, 17 January 2022 (UTC)
Wiki Education Foundation-supported course assignment
[edit]This article is or was the subject of a Wiki Education Foundation-supported course assignment. Further details are available on the course page. Student editor(s): Katchyaa.
Above undated message substituted from Template:Dashboard.wikiedu.org assignment by PrimeBOT (talk) 16:49, 17 January 2022 (UTC)
Some Potential References Added:
[edit]Crager, S. (2014). Improving global access to new vaccines: Intellectual property, technology transfer, and regulatory pathways. American Journal of Public Health, 104(11), E85-91.
Diependaele, L., Cockbain, J., & Sterckx, S. (2017). Raising the Barriers to Access to Medicines in the Developing World – The Relentless Push for Data Exclusivity. Developing World Bioethics, 17(1), 11-21.
J C Cohen-Kohler. (2007). The Morally Uncomfortable Global Drug Gap. Clinical Pharmacology & Therapeutics, 82(5), 610-4.
Hogerzeil, H. V., Iyer, J. K., Urlings, L., Prasad, T., & Brewer, S. (2014). Is the pharmaceutical industry improving with regard to access to essential medicines? The Lancet Global Health,2(3). doi:10.1016/s2214-109x(13)70159-1
Schuklenk, U., & Ashcroft, R. (2002). Affordable access to essential medication in developing countries: Conflicts between ethical and economic imperatives. Journal Of Medicine And Philosophy, 27(2), 179-195.
Stevens, H., & Huys, I. (2017). Innovative Approaches to Increase Access to Medicines in Developing Countries. Frontiers in Medicine, 4, 218.
Wiernikowski, J., & MacLeod, S. (2014). Regulatory and logistical issues influencing access to antineoplastic and supportive care medications for children with cancer in developing countries. Pediatric Blood & Cancer,61(8), 1513-1517. — Preceding unsigned comment added by ChiaO (talk • contribs) 04:33, 7 March 2018 (UTC)
Rearrangement of headers
[edit]Hi! I'm planning on rearranging some of the headers. Mostly, condensing all the HIV information under a header called "differences by sector" or "sector", switching vaccines to that header, and making another called "differences by country" or something. Thoughts?
Katchyaa (talk) 05:52, 27 April 2018 (UTC)
- Sorry, the HIV information under a header "Epidemics and access" Katchyaa (talk) 21:56, 27 April 2018 (UTC)
- B-Class medicine articles
- High-importance medicine articles
- B-Class society and medicine articles
- Unknown-importance society and medicine articles
- Society and medicine task force articles
- All WikiProject Medicine pages
- B-Class pharmacology articles
- High-importance pharmacology articles
- WikiProject Pharmacology articles